# TrumpRx

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/trumprx
Canonical HTML page: https://getbiobrief.com/entity/trumprx

## Timeline

- **2029-01-01**: Operational Launch — New facilities expected to come online to support next-gen drug production.
- **2026-03-20**: Construction Start — Anticipated ground-breaking for the two new advanced manufacturing sites.
- **2026-02-23**: Manufacturing Expansion — AbbVie announces $380 million investment for North Chicago API facilities.
- **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.

## Recent coverage (3 stories)

### Pharma Giants Limit TrumpRx Participation to 12% of Branded Drugs, Protecting Blockbusters
2026-07-19 23:26:19 · Sentiment: Negative · Impact: 6/10 · Sources: 7

Biopharma companies cooperated just enough to avoid tariffs, placing only 92 products on TrumpRx while keeping high-margin cancer, HIV, and inflammation therapies off the discount menu—revealing industry’s strategic calculus.
Full story: https://getbiobrief.com/story/trumprx-biopharma-strategy-12-percent

### Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable
2026-07-16 13:49:27 · Sentiment: Neutral · Impact: 6/10 · Sources: 12

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.
Full story: https://getbiobrief.com/story/trumprx-pharma-limited-coverage-92-deals

### AbbVie Commits $380M to U.S. Manufacturing in $100B Reshoring Push
2026-02-25 00:14:40 · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
Full story: https://getbiobrief.com/story/abbvie-380-million-us-manufacturing-investment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.